GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite
GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite of image analysis tools that detect and help characterize tiny changes in physical structures over time. The firm's image-based biomarker solutions are designed to accelerate the pharmaceutical R&D process by rapidly measuring the efficacy and safety of drug compounds. The technology might also be leveraged to improve treatment planning and diagnosis for patients. GE plans to collaborate with VirtualScopics to advance the application of its imaging technology in clinical trials. The firm's proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single 3D model.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.